NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today announced a second collaboration with Takeda Pharmaceuticals to use its technology to assist in the development of drugs.
Under the agreement, German firm Kinaxo will employ its quantitative phosphoproteomics technology, PhosphoScout, in the research, allowing Takeda to make early educated decisions on drug efficacy and safety, Kinaxo said. PhosphoScout uses mass spectrometry methods to enable unbiased quantification of about 15,000 phosphorylation sites in one experiment.
Financial and other terms of the deal were not disclosed.
Kinaxo and Takeda inked an agreement in 2008 for use of Kinaxo's KinaTor chemical proteomics technology.